EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?

Bibliography

• BUNN PA Jr, FRANKLIN W: Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin. Oncol. (2002) 29(Suppl. 14):38-44.
   PubMed Web of Science ®Google Scholar
• NATALE RB: Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. Clin. Lung Cancer (2003) 5(Suppl. 1): S11-S17.
   PubMedGoogle Scholar
• FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. (2003) 21:2237-2246.
   PubMed Web of Science ®Google Scholar
• KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290:2149-2158.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, CHACHOUA A, HAMMOND L et al.: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22:3238-3247.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132.
   PubMed Web of Science ®Google Scholar
• TSAO MS, SAKURADA A, CUTZ JC et al.: Erlotinib in lung cancer molecular and clinical predictors of outcome. N. Engl. J. Med. (2005) 353:133-144.
   PubMed Web of Science ®Google Scholar
• HIRSCH FR, VARELLA-GARCIA M, BUNN PA Jr et al.: Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. (2006) 24:5034-5042.
   PubMed Web of Science ®Google Scholar
• PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
   PubMed Web of Science ®Google Scholar
• CAPPUZZO F, HIRSCH FR, ROSSI E et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. (2005) 97:643-655.
   PubMed Web of Science ®Google Scholar
• THATCHER N, CHANG A, PARIKH P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet (2005) 366:1527-1537.
   PubMed Web of Science ®Google Scholar
• EBERHARD DA, JOHNSON BE, AMLER LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. (2005) 23:5900-5909.
   PubMed Web of Science ®Google Scholar
• LEE DH, HAN JY, LEE HG et al.: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin. Cancer Res. (2005) 11:3032-3037.
   PubMed Web of Science ®Google Scholar
• GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J. Clin. Oncol. (2007) 25(12):1545-1552.
   PubMed Web of Science ®Google Scholar
• HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:5856-5858.
   PubMed Web of Science ®Google Scholar
• CLARK GM, ZBOROWSKI D, SANTABARBARA P et al.: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the national cancer institute of Canada clinical trials group study BR.21. Clin. Lung Cancer (2006) 7(6):389-394.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-CESPEDES M, AHRENDT SA, PIANTADOSI S et al.: Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. (2001) 61:1309-1313.
   PubMed Web of Science ®Google Scholar
• AHRENDT SA, DECKER PA, ALAWI EA et al.: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001)92:1525-1530.
   PubMed Web of Science ®Google Scholar
• SLEBOS RJ, HRUBAN RH, DALESIO O et al.: Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Natl. Cancer Inst. (1991) 83:1024-1027.
   PubMed Web of Science ®Google Scholar
• PAO W, WANG TY, RIELY GJ et al.: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. (2005) 2:E17.
   PubMed Web of Science ®Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
   PubMed Web of Science ®Google Scholar
• PAEZ JG, JÄ;NNE PA, LEE JC et al.: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
   PubMed Web of Science ®Google Scholar
• PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancer from “never-smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc.Natl. Acad. Sci. USA (2004) 101:13306-13311.
   PubMed Web of Science ®Google Scholar
• TAKANO T, OHE Y, SAKAMOTO H et al.: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:6829-6837.
   PubMed Web of Science ®Google Scholar
• SHIGEMATSU H, LIN L, TAKAHASHI T et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. (2005) 97:339-346.
   PubMed Web of Science ®Google Scholar
• PHAM D, KRIS MG, RIELY GJ et al.: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J. Clin. Oncol. (2006) 24:1700-1704.
   PubMed Web of Science ®Google Scholar
• GREULICH H, CHEN TH, FENG W et al.: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. (2005) 2:E313.
   PubMed Web of Science ®Google Scholar
• MARCHETTI A, FELICIONI L, BUTTITTA F: Assessing EGFR mutations. N. Engl. J. Med. (2006) 354:526-528.
   PubMedGoogle Scholar
• HAN SW, KIM TY, HWANG PG et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. (2005) 23:2493-2501.
   PubMed Web of Science ®Google Scholar
• KIM KS, JEONG JY, KIM YC et al.: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. (2005) 11:2244-2251.
   PubMed Web of Science ®Google Scholar
• CORTES-FUNES H, GOMEZ C, ROSELL R et al.: Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-smal lcell lung cancer patients. Ann. Oncol. (2005) 16:1081-1086.
   PubMed Web of Science ®Google Scholar
• VILLAFLOR VM, BUCKINGHAM L, GALE M et al.: EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts). Proc. Am. Soc. Clin. Oncol. (2005) 23(S639):7077.
   Google Scholar
• CHOU TY, CHIU CH, LI LH et al.: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. (2005) 11:3750-3757.
   PubMed Web of Science ®Google Scholar
• TARON M, ICHINOSE Y, ROSELL R et al.: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. (2005) 11:5878-5885.
   PubMed Web of Science ®Google Scholar
• MU XL, LI LY, ZHANG XT et al.: Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin. Cancer Res. (2005) 11:4289-4294.
   PubMed Web of Science ®Google Scholar
• ZHANG XT, LI LY, MU XL et al.: The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol. (2005) 16(8):1334-1342.
   PubMed Web of Science ®Google Scholar
• MITSUDOMI T, KOSAKA T, ENDOH H et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment inpatients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. (2005) 23:2513-2520.
   PubMed Web of Science ®Google Scholar
• CAPPUZZO F, LIGORIO C, JANNE PA et al.: Prospective study of gefitinib in EGFR FISH positive/P-Akt positive or never smoker patients with advanced non-small cell lung cancer (NSCLC): the ONCOBELL trial. J. Clin. Oncol. (2007) 25(16):2248-2255.
   PubMed Web of Science ®Google Scholar
• SEQUIST LV, MARTINS RG, SPIGEL D et al.: iTARGET: a Phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. Proc. Am. Soc. Clin. Oncol. (2007) 25(S18):A7504.
   Web of Science ®Google Scholar
• PAZ-ARES L, SANCHEZ JM, GARCÍA-VELASCO A et al.: A prospective Phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2006) 24(S18):7020.
   Web of Science ®Google Scholar
• INOUE A, SUZUKI T, FUKUHARA T et al.: Prospective Phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. (2006) 24:3340-3346.
   PubMed Web of Science ®Google Scholar
• OKAMOTO I, KASHII T, URATA Y et al.: EGFR mutation-based Phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): results of West Japan thoracic oncology group trial (WJTOG0403). Proc. Am. Soc. Clin. Oncol. (2006) 24(S382):7073.
   Google Scholar
• SUTANI A, NAGAI Y, UDAGAWA K et al.: Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp. Proc. Am. Soc. Clin. Oncol. (2006) 24(S383):7076.
   Google Scholar
• SUNAGA N, YANAGITANI N, KAIRA K et al.: Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. Proc. Am. Soc. Clin Oncol. (2006) 24(S18):7183.
   Google Scholar
• ASAHINA H, YAMAZAKI K, KINOSHITA I et al.: Phase II study of gefitinib as a first-line therapy for advanced non-small cell lung cancers with epidermal growth factor receptor (EGFR) gene mutations. Proc. Am. Soc. Clin. Oncol. (2006) 24(S18):13014.
   Google Scholar
• RIELY GJ, PAO W, PHAM D et al.: Clinical course of patients with non small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. (2006) 12:839-844.
   PubMed Web of Science ®Google Scholar
• JACKMAN DM, YEAP BY, SEQUIST LV et al.: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. (2006) 12:3908-3914.
   PubMed Web of Science ®Google Scholar
• BELL DW, LYNCH TJ, HASERLAT SM et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. (2005) 23(31):8081-8092.
   PubMed Web of Science ®Google Scholar
• KOSAKA T, YATABE Y, ONOZATO R et al.: Prognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early stage lung adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2007) 25(S18):A7574.
   Web of Science ®Google Scholar
• SHEPHERD FA, DING K, SAKURADA A et al.: Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National cancer institute of cancer. Proc. Am. Soc. Clin. Oncol. (2007) 25(S18):A7571.
   Google Scholar
• HIRSCH FR, VARELLA-GARCIA M, MCCOY J et al.: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a southwest oncology group study. J. Clin. Oncol. (2005) 23:6838-6845.
   PubMed Web of Science ®Google Scholar
• BAILEY LR, KRIS M, WOLF M et al.: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc. Am. Assoc. Cancer Res. (2003) 44:LB1362-170.
   Google Scholar
• CAPPUZZO F, GREGORC V, ROSSI E et al.: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. (2003) 21:2658-2663.
   PubMed Web of Science ®Google Scholar
• WANG SE, NARASANNA A, PEREZ-TORRES M et al.: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 10(1):25-38.
   PubMed Web of Science ®Google Scholar
• MARCHETTI A, MARTELLA C, FELICIONI L et al.: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. (2005) 23:857-865.
   PubMed Web of Science ®Google Scholar
• RODENHUIS S, SLEBOS RJC, BOOT AJM et al.: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. (1988) 48:5738-5741.
   PubMed Web of Science ®Google Scholar
• SUZUKI Y, ORITA M, SHIRAISHI M et al.: Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1990) 5:1037-1043.
   PubMed Web of Science ®Google Scholar
• NELSON HH, CHRISTIANI DC, MARK EJ et al.: Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J. Natl. Cancer Inst. (1999) 91:2032-2038.
   PubMed Web of Science ®Google Scholar
• BROERMANN P, JUNKER K, BRANDT BH et al.: Trimodality treatment in stage III nonsmall cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer (2002) 94:2055-2062.
   PubMed Web of Science ®Google Scholar
• GROSSI F, LOPREVITE M, CHIARAMONDIA M et al.: Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur. J. Cancer (2003) 39:1242-1250.
   PubMed Web of Science ®Google Scholar
• HUNCHAREK M, MUSCAT J, GESCHWIND JF: K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (1999) 20:1507-1510.
   PubMed Web of Science ®Google Scholar
• SHIGEMATSU H, TAKAHASHI T, NOMURA M et al.: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. (2005) 65:1642-1646.
   PubMed Web of Science ®Google Scholar
• KOSAKA T, YATABE Y, ENDOH H et al.: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. (2004) 64:8919-8923.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA T, KONDO M, GOTO Y et al.: EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci. (2006) 97:753-759.
   PubMed Web of Science ®Google Scholar
• SUZUKI M, SHIGEMATSU H, IIZASA T et al.: Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer (2006) 106:2200-2207.
   PubMed Web of Science ®Google Scholar
• CONDE E, ANGULO B, TANG M et al.: Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin. Cancer Res. (2006) 12(3 Part 1):710-717.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, GALLEGOS RUIZ M, LE CHEVALIER T et al.: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a Phase II study. Clin. Cancer Res. (2006) 12:6049-6055.
   PubMed Web of Science ®Google Scholar
• JACKMAN DM, YEAP BY, LINDEMAN NI et al.: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol. (2007) 25(7):760-766.
   PubMed Web of Science ®Google Scholar
• MASSARELLI E, VARELLA-GARCIA M, TANG X et al.: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. (2007) 13(10):2890-2896.
   PubMed Web of Science ®Google Scholar
• STEPHENS P, HUNTER C, BIGNELL G et al.: Lung cancer: intrageing ERBB2 kinase mutations in tumours. Nature (2004) 431:525-526.
   PubMed Web of Science ®Google Scholar
• CAPPUZZO F, BEMIS L, VARELLA-GARCIA M: HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N. Engl. J. Med. (2006) 354:2619-2621.
   PubMed Web of Science ®Google Scholar
• HAN SW, KIM TY, JEON YK et al.: Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res. (2006) 12:2538-2544.
   PubMed Web of Science ®Google Scholar
• PAO W, MILLER AV, POLITI KA et al.: Aquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. (2005) 2(3):E73.
   PubMed Web of Science ®Google Scholar
• BALAK MN, GONG Y, RIELY GJ et al.: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. (2006) 12(21):6494-6501.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI S, BOGGON TJ, DAYARAM T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2005) 352(8):786-792.
   PubMed Web of Science ®Google Scholar
• ENGELMAN JA, ZEJNULLAHU K, MITSUDOMI T et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 316(5827):1039-1043.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTI A, LOEFFLER JS, DYSON NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. (2002) 62:200-207.
   PubMed Web of Science ®Google Scholar
• MORGILLO F, KIM WY, KIM ES et al.: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res. (2007) 13(9):2795-2803.
   PubMed Web of Science ®Google Scholar
• WEST HL, FRANKLIN WA, MCCOY J et al.: Gefitinib therapy in advanced bronchioloalveolar carcinoma: southwest oncology group study S0126. J. Clin. Oncol. (2006):1807-1813.
   PubMed Web of Science ®Google Scholar
• HIRSCH F, VARELLA-GARCIA M, CAPPUZZO F et al.: Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. (2007) 18(4):752-760.
   PubMed Web of Science ®Google Scholar